Loading
LifeMD, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 12 Sept 2024.
LifeMD, Inc.: what insiders have been doing
LifeMD, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 8 insiders have disclosed 13 filings since 18 October 2025.
There is no open-market purchase to report; the filings show 1 sale worth €47k by 1 insider. Biggest ticket of the year: €47k, sold by Friedeman Jessica and made public on 11 December 2025.
Typically, a trade is published a median of 7 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 5,811 companies) published 19 filings over the same period, against 13 filings here. Since 2021, the database holds 35 purchases and 14 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 194.1 m USD and net income at 14.4 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
129
Thresholds
n/a
Buy Volume
€2M
35 ops. · all time
Sell Volume
€4M
14 ops. · all time
Who traded when
BuySaleJustin Schreiber8 sales
Jessica Friedeman2 sales
Eric Harold Yecies1 sale
Marc David Benathen1 sale
Nicholas P. Alvarez1 sale
Stefan Galluppi1 sale
Since the insiders bought
- +10.6%Entry US$5.27 · Close at T+365 US$5.83
- +215.5%Entry US$2.39 · Close at T+365 US$7.54
- +335.9%Entry US$1.95 · Close at T+365 US$8.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate LifeMD, Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$8.13.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 4,641 of 24,148 companies
67.3
score / 100
Value60
Quality74
FCF yld-1.1%
Earn yld10.0%
EV/EBITDA·
ROE·
Gross mgn86%
Net mgn5.8%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.37
Analyst consensus
8 analystsStrong buy
US$5.00Target US$8.13(+243%)US$15.00
Income statement
RevenueUS$194.1M
Gross profitUS$166.3M86% margin
EBITDA-US$1.5M-1% margin
Net incomeUS$11.2M0.1% margin
Valuation
PER (forward)6.2x
P/Book14.2x
Beta1.99
Balance sheet & cash
Market capUS$114.4M
Total debtUS$6.3M
Free Cash Flow-US$1.2M
Debt / Equity76%
Profitability & ownership
ROE-515.9%
ROA-18.9%
% insiders15.8%
% institutions47.4%
Last declaration on 18 August 2026
Declarations129 total
35,000 shares0Common StockSEC:0000912282-26-001129:0
50,000 shares0Common StockSEC:0000912282-26-001125:0
35,000 shares0Common StockSEC:0000912282-26-001125:1
35,000 shares0Common StockSEC:0000912282-26-001097:0
50,000 shares0Common StockSEC:0000912282-26-001092:0
35,000 shares0Common StockSEC:0000912282-26-001092:1
24,648 shares0Common StockSEC:0000912282-26-001095:2
35,000 shares0Common StockSEC:0000912282-26-001090:0
50,000 shares0Common StockSEC:0000912282-26-001095:0
6,162 shares0Common StockSEC:0000912282-26-001095:1
337,500 shares0Common StockSEC:0000912282-26-000709:0
200,000 shares0Common SharesSEC:0000912282-26-000552:0
15,000 shares@ US$3.610522.9% of flowCommon StockSEC:0000912282-25-001395:0
22,365 shares0Common StockSEC:0000912282-25-001048:0
22,365 shares0Common StockSEC:0000912282-25-001050:0
22,365 shares0Common StockSEC:0000912282-25-001041:0
22,365 shares0Common StockSEC:0000912282-25-001038:0
22,365 shares0Common StockSEC:0000912282-25-001036:0
75,000 shares@ US$5.916892.9% of flowCommon SharesSEC:0000912282-25-000978:0
50,000 shares0Common StockSEC:0000912282-25-000922:0
20,000 shares0Common StockSEC:0000912282-25-000917:0
25,000 shares0Common StockSEC:0000912282-25-000920:0
30,000 shares0Common StockSEC:0000912282-25-000915:0
50,000 shares0Common StockSEC:0000912282-25-000913:0
30,000 shares0Common StockSEC:0000912282-25-000906:0
25 of 129 declarations
About LifeMD, Inc.
LifeMD, Inc. is a U.S.-based telehealth company listed on the NASDAQ in the United States, operating in a healthcare segment that remains highly competitive but structurally attractive as care delivery continues to digitize. Built around a direct-to-patient model, the company has evolved into an integrated virtual care platform that combines online medical consultations, diagnostics, pharmacy fulfillment, and care navigation. The business is led by founder Justin Schreiber, who has served as Chairman and CEO since 2018, providing leadership continuity that is often important in a growth-oriented healthcare services story.
LifeMD positions itself as a 50-state direct-to-patient telehealth provider, meaning it can serve patients across all 50 U.S. states through its affiliated medical network and proprietary digital infrastructure. Its portfolio spans virtual primary care, diagnostic testing, men’s and women’s health, allergy and asthma care, dermatology, and other on-demand care services. The company also emphasizes nationwide mail-order pharmacy capabilities, lab testing, and a proprietary platform designed to streamline access, reduce friction, and improve the patient experience.
Read moreShow less
From a competitive standpoint, LifeMD operates in a crowded market that includes telehealth specialists, payer-backed virtual care platforms, and digital health providers focused on specific therapeutic categories. Its differentiation is less about video visits alone and more about integrating the full care journey: consultation, prescription, follow-up, testing, and medication delivery. That integrated model can support repeat usage and better patient retention, although it also requires meaningful spending on marketing, compliance, and operational execution.
LifeMD highlights its national footprint and consumer-oriented model, with care available in all 50 states and membership-based offerings. According to its 2024 annual report, the company had more than 75,000 patient subscribers as of December 31, 2024, which suggests a business that is still mid-stage in scale but already material within its niche.
Recent developments are also relevant. In 2026, LifeMD reported full-year 2025 results showing telehealth revenue growth, alongside higher selling and marketing spending to support expansion, particularly in virtual primary care. For investors, the equity story combines growth potential, recurring revenue characteristics, and exposure to execution risk in a regulated U.S. healthcare market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
